Mei Ri Jing Ji Xin Wen·2025-08-27 23:33Group 1 - Otsuka Pharmaceutical's new ADHD drug centanafadine has received clinical trial approval in China, which is significant as it shows promising results in foreign Phase III clinical trials for treating ADHD in children and adolescents [1] - Tianxing Medical has submitted its listing application to the Hong Kong Stock Exchange, positioning itself as the largest domestic sports medicine company by sales revenue in 2024, with products covering over a thousand hospitals [2] - China National Pharmaceutical Group reported a 6.71% decline in revenue to 17.076 billion yuan and a 16.19% drop in net profit to 294 million yuan for the first half of 2025, impacted by industry policies and competition [3] Group 2 - Yiling Pharmaceutical achieved a 26.03% increase in net profit to 669 million yuan in the first half of 2025, despite a 12.26% decline in revenue to 4.04 billion yuan, indicating effective cost control and product optimization [4] - The company plans to distribute a cash dividend of 3 yuan for every 10 shares, reflecting its commitment to shareholder returns [4]